Bauxite

Australian Bauxite Ltd (ASX:ABX) Half Yearly Report

🕔9/13/2018 10:38:33 AM

Australian Bauxite Ltd (ASX:ABX) provides the Company's Half Yearly Report.

Read Full Article

Queensland Bauxite Ltd (ASX:QBL) Letter from the Chairperson

🕔8/22/2018 9:32:46 AM

The Board of Queensland Bauxite Limited (ASX:QBL) is pleased to present a set of proposed resolutions and explanatory statements, which will see the merger of Medical Cannabis Limited into the Company and the acquisition of MedCan Australia, enabling the Company to have all the licences and facilities currently needed, to progress the Cannabis business and humanitarian goals of the company.

Read Full Article

Queensland Bauxite Ltd (ASX:QBL) to Acquire International Health Food Brands

🕔8/16/2018 12:34:30 PM

The Board of Queensland Bauxite Limited (ASX:QBL) is pleased to advise that it has entered into a Heads of Agreement with Sebastian and Samuel Edwards to acquire their Health Food Brands.

Read Full Article

Australian Bauxite Ltd (ASX:ABX) ALCORE Limited to Have Global Licence for Bauxite Refining

🕔8/8/2018 9:44:38 AM

Australian Bauxite Limited (ASX:ABX) is pleased to announce that its wholly-owned subsidiary, ALCORE Limited will have global licence rights for bauxite refining using the ALCORE technology.

Read Full Article

Queensland Bauxite Ltd (ASX:QBL) Ground-breaking Discovery in Medicinal Cannabis Research

🕔8/1/2018 5:22:57 PM

The Board of Queensland Bauxite (ASX:QBL) is pleased to announce a materially positive update regarding the company's research into the use of medical cannabis in autoimmune disease treatment.

Read Full Article

Queensland Bauxite Ltd (ASX:QBL) Quarterly Report

🕔8/1/2018 3:54:15 PM

Queensland Bauxite Ltd (ASX:QBL) provides the Company's Quarterly Report.

Read Full Article

Queensland Bauxite Ltd (ASX:QBL) Recompliance Update

🕔8/1/2018 10:07:25 AM

Further to the Transformation Announcement made on 20 June 2018, the Board of Queensland Bauxite Limited (ASX:QBL) has recognised that due to current market conditions, the intended capital raise at 8c is no longer an immediate practical option. As a result, the Board has decided to amend the raising price for the recompliance.

Read Full Article